Jury Hands Down a Verdict in Prevagen Deceptive Marketing Case
Verdict comes nine years after TINA.org alerted regulator to supplement’s unsubstantiated health claims.
TA-65
In August 2012, a class action was brought on behalf of New Yorkers claiming, among other things, that the makers of pill, TA-65, which is marketed as an anti-aging supplement, “have failed to reasonably warn consumers of the potential dangerous consequences associated with TA-65 telomerase activation and malignant tumor formation.” (Egan, et al. v. Telomerase Activation Sciences, Inc. et al., Case No. 652533/2012, S.C.N.Y.)
The Latest
JBS: ‘Net Zero by 2040’
Regulators have a beef with company’s climate pledge.
Gift Card for a Five-Star Amazon Review
Consumers need to be wary of undisclosed incentivized reviews.
When Privacy Concerns and Deceptive Marketing Issues Intersect
Why TINA.org supports FTC’s proposed changes to COPPA Rule but pushes for more.
H&R Block
FTC alleges company pressures consumers into overpaying for its tax filing software.